Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05382325 · ClinicalTrials.gov registry record · Phase 1

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 1
Development phase
70
Enrollment target
8
Study locations

NCT05382325 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 70 participants, below the 233-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (70% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05382325, a Phase 1 study of Advanced or Metastatic Solid Tumors, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
70 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.

Conditions Studied

Advanced or Metastatic Solid Tumors

Interventions

  • BIOLOGICAL Pembrolizumab
  • BIOLOGICAL MK-1484

Study Locations (8)

Other

  • Rambam Health Care Campus-Oncology ( Site 0021) - Haifa
  • Sheba Medical Center-ONCOLOGY ( Site 0020) - Ramat Gan
  • Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037) - Utrecht

South Dakota

  • Sanford Cancer Center ( Site 0005) - Sioux Falls

Texas

  • NEXT Oncology ( Site 0001) - San Antonio

Ontario

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011) - Toronto

North Holland

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0035) - Amsterdam

South Holland

  • Erasmus Medisch Centrum-Medical Oncology ( Site 0036) - Rotterdam

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2022-06-16
Est. Completion 2026-07-31
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05382325

The ClinicalTrials.gov registry entry for NCT05382325 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 233-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (70% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05382325 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Other, South Dakota, Texas.

Frequently Asked Questions

What is clinical trial NCT05382325 about?

NCT05382325 is a clinical study titled "A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)". The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.

What is the current status of trial NCT05382325?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2022-06-16. Estimated completion is 2026-07-31.

What conditions does trial NCT05382325 study?

This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.

What interventions are being tested in trial NCT05382325?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-1484 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05382325?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05382325 being conducted?

This trial has 8 study locations across South Dakota, Texas, Ontario, North Holland, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced or Metastatic Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced or Metastatic Solid Tumors

All registered trials for this condition

South Dakota

All trials with a study site in South Dakota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.